vs
Side-by-side financial comparison of FIRST MID BANCSHARES, INC. (FMBH) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
FIRST MID BANCSHARES, INC. is the larger business by last-quarter revenue ($88.2M vs $86.8M, roughly 1.0× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 3.4%). FIRST MID BANCSHARES, INC. produced more free cash flow last quarter ($124.0M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 5.0%).
First Mid Bancshares Inc. is a U.S.-headquartered regional financial services holding company. It provides full-range retail and commercial banking products, wealth management, insurance solutions, and agricultural financing, mainly serving individual consumers, small and medium-sized enterprises, and agricultural clients across multiple Midwestern states including Illinois, Missouri, and Indiana.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FMBH vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $88.2M | $86.8M |
| Net Profit | $23.7M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 34.0% | -84.7% |
| Net Margin | 26.8% | — |
| Revenue YoY | 3.4% | 17.7% |
| Net Profit YoY | 23.5% | — |
| EPS (diluted) | $0.98 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $88.2M | $86.8M | ||
| Q3 25 | $89.3M | $67.5M | ||
| Q2 25 | $87.5M | $60.0M | ||
| Q1 25 | $84.3M | $49.3M | ||
| Q4 24 | $85.3M | $73.7M | ||
| Q3 24 | $80.6M | $58.6M | ||
| Q2 24 | $79.2M | $31.1M | ||
| Q1 24 | $79.9M | $715.0K |
| Q4 25 | $23.7M | — | ||
| Q3 25 | $22.5M | $-91.3M | ||
| Q2 25 | $23.4M | $-111.7M | ||
| Q1 25 | $22.2M | $-116.2M | ||
| Q4 24 | $19.2M | — | ||
| Q3 24 | $19.5M | $-83.5M | ||
| Q2 24 | $19.7M | $-97.1M | ||
| Q1 24 | $20.5M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 34.0% | -84.7% | ||
| Q3 25 | 32.2% | -140.7% | ||
| Q2 25 | 34.4% | -189.8% | ||
| Q1 25 | 33.4% | -245.8% | ||
| Q4 24 | 29.7% | -117.5% | ||
| Q3 24 | 31.5% | -152.1% | ||
| Q2 24 | 33.7% | -327.6% | ||
| Q1 24 | 33.7% | -16464.6% |
| Q4 25 | 26.8% | — | ||
| Q3 25 | 25.2% | -135.3% | ||
| Q2 25 | 26.8% | -186.2% | ||
| Q1 25 | 26.3% | -235.5% | ||
| Q4 24 | 22.5% | — | ||
| Q3 24 | 24.2% | -142.7% | ||
| Q2 24 | 24.9% | -312.2% | ||
| Q1 24 | 25.6% | -15800.8% |
| Q4 25 | $0.98 | — | ||
| Q3 25 | $0.94 | — | ||
| Q2 25 | $0.98 | $-0.33 | ||
| Q1 25 | $0.93 | $-0.36 | ||
| Q4 24 | $0.81 | $-0.24 | ||
| Q3 24 | $0.81 | $-0.28 | ||
| Q2 24 | $0.82 | $-0.34 | ||
| Q1 24 | $0.86 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | $354.5M | — |
| Stockholders' EquityBook value | $958.7M | $698.6M |
| Total Assets | $8.0B | $913.2M |
| Debt / EquityLower = less leverage | 0.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M | ||
| Q1 24 | — | $356.2M |
| Q4 25 | $354.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $958.7M | $698.6M | ||
| Q3 25 | $932.2M | $702.3M | ||
| Q2 25 | $894.1M | $698.5M | ||
| Q1 25 | $870.9M | $767.9M | ||
| Q4 24 | $846.4M | $710.4M | ||
| Q3 24 | $858.5M | $773.5M | ||
| Q2 24 | $813.6M | $768.5M | ||
| Q1 24 | $798.0M | $680.0M |
| Q4 25 | $8.0B | $913.2M | ||
| Q3 25 | $7.8B | $904.9M | ||
| Q2 25 | $7.7B | $907.4M | ||
| Q1 25 | $7.6B | $966.7M | ||
| Q4 24 | $7.5B | $910.4M | ||
| Q3 24 | $7.6B | $991.1M | ||
| Q2 24 | $7.6B | $964.3M | ||
| Q1 24 | $7.7B | $869.8M |
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $130.9M | $-52.6M |
| Free Cash FlowOCF − Capex | $124.0M | $-61.9M |
| FCF MarginFCF / Revenue | 140.6% | -71.3% |
| Capex IntensityCapex / Revenue | 7.8% | 10.7% |
| Cash ConversionOCF / Net Profit | 5.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | $207.9M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $130.9M | $-52.6M | ||
| Q3 25 | $33.0M | $-78.7M | ||
| Q2 25 | $7.7M | $-67.4M | ||
| Q1 25 | $47.9M | $-103.7M | ||
| Q4 24 | $124.4M | $-73.3M | ||
| Q3 24 | $33.1M | $-59.0M | ||
| Q2 24 | $24.0M | $-98.4M | ||
| Q1 24 | $29.0M | $-122.3M |
| Q4 25 | $124.0M | $-61.9M | ||
| Q3 25 | $31.9M | $-89.5M | ||
| Q2 25 | $6.0M | $-74.9M | ||
| Q1 25 | $46.0M | $-109.9M | ||
| Q4 24 | $119.5M | $-77.5M | ||
| Q3 24 | $32.0M | $-61.3M | ||
| Q2 24 | $22.9M | $-98.9M | ||
| Q1 24 | $27.6M | $-126.5M |
| Q4 25 | 140.6% | -71.3% | ||
| Q3 25 | 35.8% | -132.7% | ||
| Q2 25 | 6.8% | -124.9% | ||
| Q1 25 | 54.5% | -222.8% | ||
| Q4 24 | 140.0% | -105.1% | ||
| Q3 24 | 39.7% | -104.6% | ||
| Q2 24 | 28.9% | -317.9% | ||
| Q1 24 | 34.5% | -17685.3% |
| Q4 25 | 7.8% | 10.7% | ||
| Q3 25 | 1.2% | 16.1% | ||
| Q2 25 | 2.0% | 12.4% | ||
| Q1 25 | 2.3% | 12.6% | ||
| Q4 24 | 5.8% | 5.7% | ||
| Q3 24 | 1.4% | 3.9% | ||
| Q2 24 | 1.4% | 1.4% | ||
| Q1 24 | 1.9% | 583.4% |
| Q4 25 | 5.53× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 0.33× | — | ||
| Q1 25 | 2.16× | — | ||
| Q4 24 | 6.49× | — | ||
| Q3 24 | 1.70× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 1.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FMBH
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
